Repligen's (RGEN) diversity of growth drivers and a strengthening bioprocess market should support a return to mid-teens organic sales growth, RBC Capital Markets said in a Tuesday note.

The Q2 results and guidance boost, reflecting a stronger H2 outlook, keep the company's growth story intact, while high-teens growth in emerging biotech indicates that the rebound in customer base is sustainable, according to the note.

While equipment sales in Q2 were lighter, the company pointed to robust sequential order growth while highlighting the positive implications for 2027, the analysts said.

RBC reiterated its outperform rating and boosted its price target to $185 from $160.

Price: 144.49, Change: -0.85, Percent Change: -0.58